Stay on the cutting edge of precision oncology
Empowering the biopharmaceutical industry to deliver breakthrough therapeutics for patients with cancer.
Precision medicine is driving a new
era in oncology drug development
Biopharma companies are at the forefront of introducing novel targeted therapies, redefining the therapeutic management of cancer. These treatments target the specific alterations or biomarkers of a patient, which can significantly extend progression-free survival compared to traditional chemotherapy or immunotherapy.1-7
More About Our ApproachHelping pharmaceutical companies accelerate precision oncology drug development
Pioneering multiomic approaches to power precision oncology with deeper insights.
Our portfolio of innovative solutions and best-in-class service spans:
Ensure your drug development programs stay ahead of the curve with Guardant Infinity. A single assay tailored to fit your needs providing comprehensive genomic and epigenomic profiling insights for biomarker discovery and development of cancer therapies today and beyond.
Explore Guardant InfinityGuardant360 CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors.8-11 With broad medicare coverage, a growing pipeline of diagnostic claims and an expanding global network, Guardant Health can help accelerate clinical development and commercial success.
Explore Guardant360 CDxLet’s get started
Contact our biopharma team to see how we can help you accelerate precision oncology and bring the next generation of cancer therapies to patients sooner.
Learn more